| For how long should the treatment with vitamin K antagonists be maintained? | |
| | |
MedLine Citation:
|
PMID: 10629413 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Studies have shown that in most patients with venous thromboembolism (VTE), continuation of treatment with vitamin K antagonists for up to 27 months significantly reduces the probability of recurrence. Likewise, prolongation of oral anticoagulation beyond 6 months is believed to be of benefit in patients with certain forms of hereditary thrombophilia. Very prolonged periods of treatment with vitamin K antagonists at standard doses, although conferring benefit regarding the risk of recurrence of VTE, are associated with an increased incidence of major bleeds and require intensive monitoring. Use of a lower intensity of anticoagulation may reduce these negative aspects and enable anticoagulation to be carried out for longer. |
| | |
Authors:
|
S Schulman |
Related Documents
:
|
23535113 - Which side of lateral ventricles to choose during external ventricular drainage in pati... 8291973 - Early and late results after bird's nest filter placement in the inferior vena cava: cl... 2702403 - Stamey needle suspension for stress urinary incontinence. a prospective study of 40 pat... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Haemostasis Volume: 29 Suppl S1 ISSN: 0301-0147 ISO Abbreviation: Haemostasis Publication Date: 1999 Dec |
Date Detail:
|
Created Date: 2000-02-25 Completed Date: 2000-02-25 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 0371574 Medline TA: Haemostasis Country: SWITZERLAND |
Other Details:
|
Languages: eng Pagination: 89-90 Citation Subset: IM |
Copyright Information:
|
Copyright 1999 S. Karger AG, Basel |
Affiliation:
|
Coagulation Unit, Department of Haematology and Infectious Disease, Karolinska Hospital, Stockholm, Sweden. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Anticoagulants / administration & dosage, therapeutic use* Humans Time Factors Venous Thrombosis / drug therapy* Vitamin K / antagonists & inhibitors* |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants; 12001-79-5/Vitamin K |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Can all patients with deep vein thrombosis receive low-molecular-weight heparin in an outpatient set...
Next Document: Should patients with venous thromboembolism and cancer be treated differently?